DYN 201
Alternative Names: DYN-201Latest Information Update: 06 Mar 2023
At a glance
- Originator Dynacure
- Developer Flamingo Therapeutics
- Class Antisense oligonucleotides
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Spastic paralysis
Most Recent Events
- 02 Mar 2023 Dynacure has merged with Flamingo Therapeutics to form Flamingo Therapeutics
- 13 Oct 2020 Dynacure in-licenses IP rights related to the development of DYN 201 from Institut du Cerveau et de la Moelle erpiniere
- 13 Oct 2020 Preclinical trials in Spastic paralysis in France (unspecified route)